<?xml version="1.0" encoding="UTF-8"?>
<p>Coagulopathy is one of the main pathologies associated with DENV infection
 <xref rid="rmv2161-bib-0084" ref-type="ref">
  <sup>84</sup>
 </xref>, 
 <xref rid="rmv2161-bib-0085" ref-type="ref">
  <sup>85</sup>
 </xref> and is also presented in cases of Covid‐19.
 <xref rid="rmv2161-bib-0086" ref-type="ref">
  <sup>86</sup>
 </xref>, 
 <xref rid="rmv2161-bib-0087" ref-type="ref">
  <sup>87</sup>
 </xref>, 
 <xref rid="rmv2161-bib-0088" ref-type="ref">
  <sup>88</sup>
 </xref> Both SARS‐CoV‐2 and dengue infections exhibit prolonged prothrombin time and partial thromboplastin time.
 <xref rid="rmv2161-bib-0089" ref-type="ref">
  <sup>89</sup>
 </xref>, 
 <xref rid="rmv2161-bib-0090" ref-type="ref">
  <sup>90</sup>
 </xref> Surprisingly, the activity of coagulation factors, including prothrombin, factors V, VII, VIII, IX, and X, antithrombin, and α2‐antiplasmin, was markedly reduced during the acute febrile stage of dengue; while in contrast, it appears to increase in the Covid‐19 patients.
 <xref rid="rmv2161-bib-0091" ref-type="ref">
  <sup>91</sup>
 </xref> Growing evidence suggests that hypercoagulable state was evident in Covid‐19 patients. This condition leads to the increasing incidence of venous and arterial thromboembolic diseases such as pulmonary embolism, venous thromboembolism, myocardial infarction, stroke, and other microvascular thrombosis (Figure 
 <xref rid="rmv2161-fig-0001" ref-type="fig">1</xref>).
 <xref rid="rmv2161-bib-0002" ref-type="ref">
  <sup>2</sup>
 </xref>, 
 <xref rid="rmv2161-bib-0092" ref-type="ref">
  <sup>92</sup>
 </xref>, 
 <xref rid="rmv2161-bib-0093" ref-type="ref">
  <sup>93</sup>
 </xref>, 
 <xref rid="rmv2161-bib-0094" ref-type="ref">
  <sup>94</sup>
 </xref>, 
 <xref rid="rmv2161-bib-0095" ref-type="ref">
  <sup>95</sup>
 </xref>, 
 <xref rid="rmv2161-bib-0096" ref-type="ref">
  <sup>96</sup>
 </xref> The pathobiology of coagulopathy in Covid‐19 is not well understood. A recent study reported the presence of antiphospholipid antibodies in Covid‐19 patients, including anticardiolipin IgA antibodies and anti‐β2‐glycoprotein I IgA and IgG antibodies, which abnormally target several phosphoproteins.
 <xref rid="rmv2161-bib-0089" ref-type="ref">
  <sup>89</sup>
 </xref> The presence of these antiphospholipid antibodies is considered associated with coagulopathy.
 <xref rid="rmv2161-bib-0097" ref-type="ref">
  <sup>97</sup>
 </xref> However, several critical illnesses and other infections also elevated the levels of these antibodies; therefore, it is speculated that the presence of these antibodies might be less associated with the occurrence of any severe coagulopathies.
 <xref rid="rmv2161-bib-0098" ref-type="ref">
  <sup>98</sup>
 </xref> Studies have also reported the presence of DIC pre‐terminally in Covid‐19 patients.
 <xref rid="rmv2161-bib-0086" ref-type="ref">
  <sup>86</sup>
 </xref>, 
 <xref rid="rmv2161-bib-0087" ref-type="ref">
  <sup>87</sup>
 </xref>, 
 <xref rid="rmv2161-bib-0088" ref-type="ref">
  <sup>88</sup>
 </xref>
</p>
